4.6 Review

Psoriasis and comorbid diseases Implications for management

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2016.07.065

关键词

cardiovascular disease; chronic kidney disease; comorbidities; Crohn's disease; depression; infection; lymphoma; metabolic syndrome; nonalcoholic fatty liver disease; psoriasis; psoriatic arthritis; screening; vaccination

资金

  1. National Institute of Arthritis and Musculoskeletal and Skin Diseases [K24AR064310, T32AR00746532, K23AR063764, K23AR068433]
  2. Dermatology Foundation Career Development Award
  3. Intramural Research Program at the National Institutes of Health [ZIAHL006193-02]
  4. National Institute for Health Research Clinician Scientist Fellowship [NIHR/CS/010/014]
  5. Pfizer Inc
  6. AbbVie
  7. Celgene
  8. Amgen
  9. Eli Lilly
  10. Janssen
  11. Novartis Corp
  12. Regeneron
  13. National Institute for Health Research [NIHR/CS/010/014] Funding Source: researchfish

向作者/读者索取更多资源

As summarized in the first article in this continuing medical education series, the currently available epidemiologic data suggest that psoriasis may be a risk factor for cardiometabolic disease. Emerging data also suggest associations between psoriasis and other comorbidities beyond psoriatic arthritis, including chronic kidney disease, inflammatory bowel disease, hepatic disease, certain malignancies, infections, and mood disorders. Recognizing the comorbid disease burden of psoriasis is essential for ensuring comprehensive care of patients with psoriasis. The clinical implications of the comorbid diseases that are associated with psoriasis and recommendations for clinical management are reviewed in this article.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据